Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Metabolic Health

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

X. Pi-Sunyer; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; D. C. Lau; C. W. le Roux; R. Violante Ortiz; C. B. Jensen; J. P. Wilding A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

W. D. Porter; P. R. Flatt; C. Hölscher; V. A. Gault Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice International Journal of Obesity
Insulin Resistance & Diabetes

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

V. Pathak; P. R. Flatt; N. Irwin Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

Liraglutide: another reason to target prediabetes?

C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Insulin Resistance & Diabetes

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial

D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Insulin Resistance & Diabetes

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Insulin Resistance & Diabetes

Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men

J. McEneny; P. A. McPherson; A. McGinty; S. S. Hull; D. R. McCance; I. S. Young Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men Ann Clin Biochem
Cholesterol

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

A. D. Miras; B. Pérez-Pevida; M. Aldhwayan; A. Kamocka; E. R. McGlone; W. Al-Najim; H. Chahal; R. L. Batterham; B. McGowan; O. Khan; V. Greener; A. R. Ahmed; A. Petrie; S. Scholtz; S. R. Bloom; T. M. Tan Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol
Insulin Resistance & Diabetes

Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease

W. P. Martin; Y. H. D. Chuah; M. Abdelaal; A. Pedersen; D. Malmodin; S. Abrahamsson; M. Hutter; C. Godson; E. P. Brennan; L. Fändriks; C. W. le Roux; N. G. Docherty Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease Front Endocrinol (Lausanne)
Chronic Kidney Disease Genetics

Regulating the effects of GPR21, a novel target for type 2 diabetes

S. Leonard; G. K. Kinsella; E. Benetti; J. B. Findlay Regulating the effects of GPR21, a novel target for type 2 diabetes Scientific reports
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page25 Page26 Page27 … Page53 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI